BGLC
BioNexus Gene Lab Corp.NASDAQHealthcare$2.26+2.44%ClosedMarket Cap: $4.1M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
0.60
P/S
0.43
EV/EBITDA
-0.63
DCF Value
$-9.07
FCF Yield
-71.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
14.8%
Operating Margin
-24.8%
Net Margin
-24.3%
ROE
-30.2%
ROA
-30.1%
ROIC
-32.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 2025 | $2.5M | 14.8% | $-702.5K | $-709.0K | $-0.39 | — |
| Q2 2025 | $2.3M | 16.3% | $-611.3K | $-616.2K | $-0.34 | — |
| Q1 2025 | $2.1M | 16.1% | $-618.4K | $-623.3K | $-0.35 | — |
| Q4 2024 | $2.5M | 12.3% | $-416.2K | $-348.3K | $-0.19 | — |
| FY 2024 | $9.5M | 13.6% | $-1.6M | $-1.6M | $-0.90 | — |
| Q3 2024 | $2.6M | 12.4% | $-1.3M | $-1.3M | $-0.75 | — |
| Q2 2024 | $2.0M | 14.6% | $259.2K | $199.1K | $0.11 | — |
| Q1 2024 | $2.4M | 15.3% | $-79.0K | $-103.8K | $-0.06 | — |
| Q4 2023 | $2.3M | 11.7% | $256.7K | $307.4K | $0.17 | — |
| FY 2023 | $9.8M | 13.6% | $-2.6M | $-2.6M | $-1.53 | — |
| Q3 2023 | $2.6M | 13.9% | $-2.5M | $-2.6M | $-1.56 | — |
| Q2 2023 | $2.6M | 13.2% | $-272.2K | $-259.3K | $-0.02 | — |